Agenus shares are trading lower. The company announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high or deficient mismatch repair.
Portfolio Pulse from Benzinga Newsdesk
Agenus Inc. shares are trading lower following the announcement of updated results from its Phase 1 clinical trial of BOT/BAL combination therapy for metastatic CRC that is not microsatellite instability-high or deficient mismatch repair.
April 12, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agenus Inc. shares are experiencing a downturn due to the latest clinical trial results of its BOT/BAL combination therapy for metastatic CRC.
The negative market reaction is likely due to investor concerns over the efficacy and future potential of Agenus's BOT/BAL combination therapy, as updated clinical trial results can significantly impact perceptions of a biotech company's pipeline value.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100